Compare Intuitive Surgical, Inc. (ISRG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Intuitive Surgical, Inc. trades at $423.96 (market cap $146.76B), while Regeneron Pharmaceuticals Inc trades at $741.17 (market cap $76.14B). The key difference: Intuitive Surgical, Inc. is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| ISRG | REGN | |
|---|---|---|
Market Cap | $146.76B | $76.14B |
Volume | 2,529,814 | 500,239 |
Sector | Health | Health |
52-Week High | $592.85 | $852.03 |
52-Week Low | $332.02 | $557.73 |
Typical Hold Time | 84 Days | 107 Days |
Enterprise Value | $141.54B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $423.96, up 2.28% with strong bullish momentum. The stock shows robust fundamentals with 2025 revenue reaching $10.06B and net income of $2.86B, maintaining 28.45% net margins. Recent quarters consistently beat EPS estimates, while technical indicators signal bullish moving averages. Analyst consensus remains strongly positive with 70% buy ratings and $480.78 price target, representing 13% upside potential.
ISRG's leadership in robotic surgery and expanding international presence in India and Japan provide growth catalysts, though China weakness and competitive pressures present risks. The stock's premium valuation (P/E 47.64) reflects high growth expectations, requiring continued execution. Current levels near resistance at $427 may test near-term momentum ahead of Q3 earnings.
Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.
The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
